Bank of America Corp DE Has $996,000 Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Bank of America Corp DE lifted its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 59.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 127,159 shares of the company's stock after buying an additional 47,439 shares during the period. Bank of America Corp DE owned about 0.28% of Y-mAbs Therapeutics worth $996,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Y-mAbs Therapeutics in the fourth quarter worth $46,000. Wells Fargo & Company MN boosted its position in Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock valued at $137,000 after purchasing an additional 6,131 shares during the last quarter. SG Americas Securities LLC boosted its position in Y-mAbs Therapeutics by 30.7% during the fourth quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock valued at $139,000 after purchasing an additional 4,163 shares during the last quarter. XTX Topco Ltd boosted its position in Y-mAbs Therapeutics by 83.8% during the fourth quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock valued at $163,000 after purchasing an additional 9,468 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its position in Y-mAbs Therapeutics by 9.4% during the fourth quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock valued at $174,000 after purchasing an additional 1,903 shares during the last quarter. Institutional investors and hedge funds own 70.85% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Morgan Stanley cut their target price on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a report on Wednesday, March 5th. Wedbush restated an "outperform" rating and set a $18.00 target price (down from $21.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, May 28th. HC Wainwright cut their target price on Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a report on Monday, May 19th. Oppenheimer cut their target price on Y-mAbs Therapeutics from $20.00 to $15.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. Finally, Bank of America lowered Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 target price on the stock. in a report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $15.60.

Y-mAbs Therapeutics Trading Down 3.5%

YMAB stock traded down $0.18 during trading on Wednesday, reaching $4.93. 153,696 shares of the stock were exchanged, compared to its average volume of 303,877. Y-mAbs Therapeutics, Inc. has a twelve month low of $3.55 and a twelve month high of $16.11. The company has a market capitalization of $223.25 million, a P/E ratio of -9.13 and a beta of 0.52. The stock has a 50 day simple moving average of $4.42 and a 200-day simple moving average of $6.05.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. Equities analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.